Biochemical Pharmacology commentaries by Mike Williams

mike_williams525454Commentaries are a widely read and widely cited feature that appear in each issue of Biochemical Pharmacology. These brief, peer reviewed articles include timely updates on topics that include: molecular aspects of disease pathophysiology; targets of drug action; aspects of the teaching and current day role of pharmacology; and regulatory and policy issues related to drug discovery thus providing a forum for debate as it relates to understanding of issues and challenges to the study of the interrelated topics of disease causality and drug discovery.

Controversy is warmly encouraged with recent Commentaries questioning progress in the treatment of cancer over the past 50 years (Vol. 78, 1083-1094, 2009) and challenging the usefulness of genomics as a tool in CNS drug discovery (Vol. 87, 1360- 1365).

Commentary topics, together with a brief outline, are submitted to the Commentaries Editor, Mike Williams to assess suitability for the journal – a process that typically takes less than a week. This avoids authors spending time writing articles that are outside areas of interest to the readership of the journal and also avoids duplication and the too frequent review of topics.

All Commentaries undergo timely and transparent peer review and, on occasions where the reviewers take issue with the topic – but neither the quality nor readability – the Commentary is published with an invitation for a “counter- Commentary”. While usually recruited via the invitation of Editorial Board members, unsolicited Commentary topics can be submitted directly to the journal.

 

Published examples

Volume 79, Issue 7, Pages 939-1082 (1 April 2010)

Endocrine disruptors and thyroid hormone physiology (Pages 939-947)
Mary-Line Jugan, Yves Levi, Jean-Paul Blondeau

 

biopharm1

 

Volume 79, Issue 6, Pages 801-938 (15 March 2010)

Good night and good luck: Norepinephrine in sleep pharmacology
(Pages 801-809)
Heather A. Mitchell, David Weinshenker

biopharm2 

 

Volume 79, Issue 5, Pages 665-800 (1 March 2010)

Measuring levels of proteins by various technologies: Can we learn more by measuring turnover? (Pages 665-668)
Michael J. Kuhar

Protein levels (the number of dots per compartment) do not change, but turnover (the rate in and out of the compartment: 1 vs. 10) does.

biopharm3 

 

Volume 79, Issue 4, Pages 525-664 (15 February 2010)

From IL-15 to IL-33: the never-ending list of new players in inflammation. Is it time to forget the humble aspirin and move ahead? (Pages 525-534)
Fulvio D’Acquisto, Francesco Maione, Magali Pederzoli-Ribeil

biopharm4

 

Volume 79, Issue 3, Pages 297-524 (1 February 2010)

Human DEAD-box protein 3 has multiple functions in gene regulation and cell cycle control and is a prime target for viral manipulation (Pages 297-306)
Martina Schröder

biopharm5

 

Volume 79, Issue 2, Pages 77-296 (15 January 2010)

Astrocytes in the damaged brain: Molecular and cellular insights into their reactive response and healing potential (Pages 77-89)
Annalisa Buffo, Chiara Rolando, Stefania Ceruti

biopharm6

 

Volume 79, Issue 1, Pages 1-76 (1 January 2010)

The Yin and Yang of vitamin D receptor (VDR) signaling in neoplastic progression: Operational networks and tissue-specific growth control (Pages 1-9)
F.C. Campbell, Haibo Xu, M. El-Tanani, P. Crowe, V. Bingham

 biopharm7